IMMUNOCORE HOLDINGS PLC - AMERICAN DEPOSITARY SHAR

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress

09 Sep 2022 10:00:00 By Nasdaq GlobeNewswire

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update

10 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022

03 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore Announces $140 Million Private Placement Financing

18 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV

11 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™

25 Jun 2022 04:00:00 By Nasdaq GlobeNewswire

Immunocore Appoints Siddharth Kaul to its Board of Directors

09 Jun 2022 07:45:00 By Nasdaq GlobeNewswire

The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

08 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

06 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

03 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

01 Jun 2022 16:30:00 By Nasdaq GlobeNewswire

Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

26 May 2022 18:00:00 By Nasdaq GlobeNewswire

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update

11 May 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the 21st Annual Needham Healthcare Conference

07 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

04 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference

09 Mar 2022 17:30:00 By Nasdaq GlobeNewswire

Immunocore Reports Full Year 2021 Financial Results and Provides Business Update

03 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

25 Feb 2022 02:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the SVB Leerink Global Healthcare Conference

11 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma

26 Jan 2022 07:00:00 By Nasdaq GlobeNewswire